15 June 2020 | News
By giving patients an ideal one-stop ecosystem providing screening, diagnostics, drug delivery, device
Image credit- shutterstock.com
Omron Healthcare India, a leading healthcare monitoring brand in the country, and Lupin Limited, a global pharma major, has announced a long-term strategic alliance to strengthen respiratory disease management facilities in India mainly focusing on Asthma and COPD patients.
Synergizing their vision of improving lives and contributing to a better society through utilization of innovative technology, the alliance aims to support the whole journey and experience of a respiratory patient right from diagnosis to treatment.
Under this collaboration, the two companies will combine their respective strengths in disease know-how and solution-creation abilities to transform the outcomes of respiratory disease management by giving patients an ideal one-stop ecosystem providing screening, diagnostics, drug delivery, device, aided with advanced technology and digital tools all under one roof.
It is expected that the partnership will lead to:
In response to signing the MoU with OMRON, Rajeev Sibal, President — India Region Formulations, Lupin Limited, mentioned LUPIN’s long association with OMRON, a global leader in healthcare monitoring, and expressed confidence that this MoU will usher a new era in terms of improving awareness, diagnosis, adherence & drug delivery, all of which are focus areas for the respiratory team. He added that devices & initiatives under this MoU will help the clinicians to significantly improve clinical outcomes and boost the quality of life of patients.
Elaborating more, Mr. Masanori Matsubara, MD, OMRON Healthcare India, said “This joint endeavor with Lupin is one of the most significant steps in the direction of achieving OMRON’s ‘Zero Asthma Events’ vision for Indian society. We are extremely hopeful & confident that our expertise in technology & monitoring will synergize well with Lupin’s capabilities in pharmaceutics to create a new business model strongly oriented towards creating value in the lives of millions of people suffering from debilitating diseases like asthma and COPD.”